Company Analysis

ABVC BioPharma, Inc. (ABVC)

Nasdaq: ABVC · Pharmaceutical Preparations · Fremont, CA · filing with the SEC since 2002
Grade3.0
◀ Past 1.3● Present 3.6▶ Future 3.4
3 est.

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2017
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Sep 30, 2017
Report filedMar 3, 2026Apr 15, 2025Mar 13, 2024Mar 31, 2023Mar 31, 2022Mar 16, 2021May 15, 2020Apr 15, 2019Apr 13, 2018Jan 16, 2018
Revenue296,0000152,430969,783355,797483,045701,7196,956··
Cost of revenue·763302,037286,4155,08618,71620,137185,280··
Gross profit·508,826-149,607683,368350,711464,329681,582-178,324··
Research and development121,085179,2721,062,9162,693,4571,003,805549,6581,048,553988,721r3,171,6653,151,162
Selling, general and administrative2,887,3582,261,3365,368,2786,067,5455,746,1194,273,4683,069,4931,588,718r811,685707,142
Total operating expenses7,151,2595,214,0686,617,127r15,797,78012,056,6798,970,1054,140,3602,606,239r4,138,750·
Operating income-7,151,259-4,705,242-6,766,734r-15,114,412-11,705,968-8,505,776-3,458,778-2,784,563r-4,138,750-3,996,342
Interest expense415,890825,8991,313,671293,968227,210405,032482,014462,751r103,46074,960
Interest and investment income167,10387,358185,481187,81743,19671,04523,3445,212r180149
Share of profit of equity-method investments-803,008·-221,888·-269,844·-210,086-193,012r··
Other income (expense), net-13,642134,4433,384-24,149r495,141r174,77092,959-5,154··
Total non-operating income (expense)-1,201,546-664,334-1,258,104r-400,184495,141-2,308,160-551,503-3,645,064r-103,280-74,811
Income before income taxes-8,352,805-5,369,576-8,024,838r-15,514,596-11,210,827-10,813,936-4,010,281-6,429,627r-4,242,030-4,071,153
Income tax expense24,154-110,539256,006797,778825,024-220,352-77,041-365,097r830830
Net income including non-controlling interests-8,376,959-5,259,037-8,280,844r-16,312,374-12,035,851-10,593,584-3,933,240-6,064,530··
Net income to non-controlling interests-468,405-356,159-492,794r110,865802,962r-10,593,584····
Net income-7,908,554-4,902,878-7,788,050r-16,423,239-12,838,813r-10,593,584-3,933,240-6,064,530r-4,242,860-4,071,983
Net income to common shareholders·5,259,037·-16,423,239-12,838,813-9,791,164····
Earnings per share, basic-0.39-0.42-1.80r-5.19r-0.51-0.50·-0.02-0.02-0.02
Earnings per share, diluted-0.39-0.42-1.80r-5.19r-0.51-0.50·-0.02-0.02-0.02
Earnings per share, basic and diluted····-0.51-0.50-0.21-0.48r-0.02-0.02
Weighted average shares, basic20,108,94411,673,9804,335,6503,166,460r25,053,52219,715,559·213,884,105213,321,921212,648,770
Weighted average shares, diluted20,108,94411,673,9804,335,6503,166,460r25,053,52219,715,559·213,884,105213,321,921212,648,770
Weighted average shares, basic and diluted····25,053,52219,715,55917,498,54311,607,103r213,321,921212,648,770
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
us-gaap:Revenues
Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfRevenue
Gross profit revenue less the cost of what it soldus-gaap:GrossProfit
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpenseNonoperating
us-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Share of profit of equity-method investments its share of companies it partly ownsus-gaap:IncomeLossFromEquityMethodInvestments
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income to non-controlling interests the share that belongs to minority holdersus-gaap:NetIncomeLossAttributableToNoncontrollingInterest
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton ABVC · research, not advice